2015
DOI: 10.1002/jnr.23588
|View full text |Cite
|
Sign up to set email alerts
|

Effects of oxaliplatin and oleic acid Gc‐protein‐derived macrophage‐activating factor on murine and human microglia

Abstract: The biological properties and characteristics of microglia in rodents have been widely described, but little is known about these features in human microglia. Several murine microglial cell lines are used to investigate neurodegenerative and neuroinflammatory conditions; however, the extrapolation of the results to human conditions is frequently met with criticism because of the possibility of species-specific differences. This study compares the effects of oxaliplatin and of oleic acid Gc-protein-derived macr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
12
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 15 publications
(13 citation statements)
references
References 29 publications
1
12
0
Order By: Relevance
“…Furthermore, disaccharides derived from chondroitin sulfate have been implicated in the inhibition of neurodegeneration by influencing microglia activation (Ebert et al, 2008) in a manner consistent with what we had observed treating microglial cells in vitro with GcMAF (Branca et al, 2015). Consistent with these evidences, experimental and clinical data suggest that chondroitin sulfate might be a useful therapeutic agent in neurological diseases that are characterized by inflammation such as Parkinson's and Alzheimer's diseases, multiple sclerosis and amyotrophic lateral sclerosis (Vallières and du Souich, 2010) that are some of the conditions successfully treated with GcMAF (Thyer et al, 2013c).…”
Section: Introductionsupporting
confidence: 74%
See 1 more Smart Citation
“…Furthermore, disaccharides derived from chondroitin sulfate have been implicated in the inhibition of neurodegeneration by influencing microglia activation (Ebert et al, 2008) in a manner consistent with what we had observed treating microglial cells in vitro with GcMAF (Branca et al, 2015). Consistent with these evidences, experimental and clinical data suggest that chondroitin sulfate might be a useful therapeutic agent in neurological diseases that are characterized by inflammation such as Parkinson's and Alzheimer's diseases, multiple sclerosis and amyotrophic lateral sclerosis (Vallières and du Souich, 2010) that are some of the conditions successfully treated with GcMAF (Thyer et al, 2013c).…”
Section: Introductionsupporting
confidence: 74%
“…It is worth noticing that, despite these obvious inconsistencies, GcMAF has been independently studied for about two decades by several research groups that reported consistent results in vitro and in vivo (for a recent review, see Ruggiero et al, 2016). My former research group, among others, has witnessed the effects of GcMAF derived from human blood on human mononuclear cells and on angiogenesis (Pacini et al, 2010;2012a), on human breast cancer cells (Pacini et al, 2012b;Thyer et al, 2013a) and on human neurons and glial cells (Morucci et al, 2015;Branca et al, 2015). We have also observed the clinical effects of GcMAF administration in the context of an integrated immunotherapeutic protocol for cancer (Ruggiero et al, 2014) and members of my former research group have described the effects of integrated GcMAF immunotherapy in diseases as diverse as cancer (Thyer et al, 2013b), chronic fatigue syndrome, multiple sclerosis, Lyme disease, amyotrophic lateral sclerosis, syphilis and autism (Thyer et al, 2013c).…”
Section: Introductionmentioning
confidence: 99%
“…In addition, the ascription of the clinical effects of GcMAF to its adjuvant activity would solve many of the inconsistencies that we have described in a recent paper [10]. The adjuvant activity of GcMAF is consistent with the molecular models we recently proposed [34], and may explain the greater efficacy of a GcMAF derivative we invented, where oleic acid was non-covalently bound to the protein [44]. imuno TM , at variance with GcMAF and Rerum  , contains neither blood-derived proteins nor animal-derived components that may interfere with features of the emulsion that are required to exert maximal adjuvant activity without side effects.…”
Section: Mechanism Of Action Of Imuno Tm As a Freund's Adjuvant Indications And Ways Of Administrationmentioning
confidence: 53%
“…Much of what is currently known about microglia, stems from in vitro studies using rodent microglia, particularly immortalized cell lines. However, there is increasing interest in the use of immortalized human microglial cell lines to advance our understanding of human microglia function and discovery of pharmacological agents that modulate microglia [37,38,53,54] .…”
Section: Minutes Minutesmentioning
confidence: 99%